Teclison is a clinical-stage biotech company that is ready for phase 3 registration. Our flagship product TEC-001 is a first-in-class compound with dual effects in killing tumors and converting tumor into a therapeutic vaccine to supercharge immunotherapy. Phase 1 clinical study achieved durable complete remission in liver cancer with a great safety profile. FDA agreed with a path of accelerated approval in the End of Phase 1 meeting. Phase 2 clinical study showed a 36% response rate with a combination of TEC-001+Keytruda in metastatic colorectal cancer, far better than 0% with Keytruda alone. Strategic alliance with Merck for further development, and licensed out the China right. Teclison seeks series B $80M investment to support clinical development, aiming to achieve market approval in liver cancer and mCRC first, and expand to all solid tumors with liver metastasis. Anticipate IPO and start negotiation of licensing & acquisition in two years for exit.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):